File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: COGENT (COlorectal cancer GENeTics): An international consortium to study the role of polymorphic variation on the risk of colorectal cancer
  • Basic View
  • Metadata View
  • XML View
TitleCOGENT (COlorectal cancer GENeTics): An international consortium to study the role of polymorphic variation on the risk of colorectal cancer
 
AuthorsTomlinson, IPM17
Dunlop, M23
Campbell, H23
Zanke, B6 20 19
Gallinger, S19 16
Hudson, T6
Koessler, T13
Pharoah, PD13
Niittymäkix, I9
Tuupanenx, S9
Aaltonen, LA9
Hemminki, K25
Lindblom, A11
Försti, A11
Sieber, O7
Lipton, L7
Van Wezel, T22
Morreau, H22
Wijnen, JT22
Devilee, P22
Matsuda, K18
Nakamura, Y18
CastellvíBel, S15
RuizPonte, C4
Castells, A15
Carracedo, A4
Ho, JWC3
Sham, P3
Hofstra, RMW5
Vodicka, P24
Brenner, H25
Hampe, J14
Schafmayer, C14 14
Tepel, J14
Schreiber, S14
Völzke, H26
Lerch, MM26
Schmidt, CA26
Buch, S14
Moreno, V15
Villanueva, CM10
Peterlongo, P12
Radice, P12
Echeverry, MM8
Velez, A1
CarvajalCarmona, L17 8
Scott, R21
Penegar, S2
Broderick, P2
Tenesa, A23
Houlston, RS2
 
KeywordsAssociation
Colorectal cancer
Polymorphism
 
Issue Date2010
 
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
 
CitationBritish Journal Of Cancer, 2010, v. 102 n. 2, p. 447-454 [How to Cite?]
DOI: http://dx.doi.org/10.1038/sj.bjc.6605338
 
AbstractIt is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT. © 2010 Cancer Research UK. All rights reserved.
 
ISSN0007-0920
2012 Impact Factor: 5.082
2012 SCImago Journal Rankings: 2.311
 
DOIhttp://dx.doi.org/10.1038/sj.bjc.6605338
 
PubMed Central IDPMC2816642
 
ISI Accession Number IDWOS:000273728500026
Funding AgencyGrant Number
Cancer Research UK
European Union
Instituto de Salud Carlos IIIFIS 05/1006
08/1359
08/1635
European CommissionFP6 Food-CT-2006-036224
Genome Canada
National Cancer Institute of Canada
Ontario Institute for Cancer Research
Academy of Finland20062011
Sigrid Juselius Foundation
Finnish Cancer Societies
German Genome Network
GACR310/07/1430
Swedish Cancer Foundation
Swedish Research Council
Fondo de Investigacion SanitariaFIS 04/1126
05/2031
05/0071
08/0025
08/1276
03-0070
Xunta de GaliciaPGIDIT07PXIB9101209PR
Fundacion de Investigacion Medica Mutua Madrilena
Ministerio de Educacion y CienciaSAF 07-64873
Asociacion Espanola contra el Cancer
Fundacion Olga Torres
Instituto de Salud Carlos III
NHMRC489418
Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government
Funding Information:

The work of UK groups is supported by grants from Cancer Research UK and the European Union. In Spain, work is supported by grants from the Instituto de Salud Carlos III, grants FIS 05/1006, 08/1359, 08/1635 and European Commission FP6 Food-CT-2006-036224 (VM). In Canada, work is supported by grants from Genome Canada (the ARCTIC Project), the National Cancer Institute of Canada (the CaRE Project) and the Ontario Institute for Cancer Research. In Finland, work is supported by grants from Academy of Finland (Finnish Centre of Excellence Program 20062011), the Sigrid Juselius Foundation, the Finnish Cancer Societies and by the European Union. The work of DFKS is supported by the German Genome Network (NGFNplus). In the Czech Republic, work is supported by GACR 310/07/1430. In Sweden, work is supported by grants from the Swedish Cancer Foundation and the Swedish Research Council. In Barcelona and Santiago (Epicolon), work is supported by grants from Fondo de Investigacion Sanitaria (FIS 04/1126, 05/2031, 05/0071, 08/0025, 08/1276), Xunta de Galicia (PGIDIT07PXIB9101209PR), Fundacion de Investigacion Medica Mutua Madrilena (CRP and SCB), Ministerio de Educacion y Ciencia (SAF 07-64873), Asociacion Espanola contra el Cancer, Fundacion Olga Torres (SCB) and Accion Transversal contra el Cancer (Instituto de Salud Carlos III). CIBERER and CIBEREHD are funded by the Instituto de Salud Carlos III. SCB is supported by a contract from the Fondo de Investigacion Sanitaria (CP 03-0070, Ministerio de Sanidad. Provision of genotyping is gratefully provided by Santiago de Compostela node of the Spanish National Genotyping Center (CeGen). In The Netherlands, work of RH is supported by the Dutch Cancer Society and the European Community, and the work of JTW, TvW, HM and PD is supported by the Dutch Cancer Society (UL2005-3247) and Fonds NutsOhra. In Hong Kong, work is supported by grants from the Michael and Betty Kadoorie Cancer Genetics Research Programme II and by the Bobby Moore Fund of Cancer Research UK. Work in Australia is conducted under the auspices of the Hilton Ludwig Cancer Metastasis Initiative and supported by a grant from the NHMRC (Project Grant 489418). In Japan, this work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The ESTHER and VERDI studies are supported by grants from the Baden Wurttemberg Ministry of Research, Science and Arts and the German Cancer Aid (Deutsche Krebshilfe, Grant M24/95/BR I). The Kiel cohort (POPGEN) is funded through the German Ministry of Education and Reserach through the POPGEN Biobank grant and the Colon Cancer Network of the German National Genome Research Network. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant no. 03ZIK012) and by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of Siemens AG. MME, AV and LC-C have received funding from Cancer Research UK and Universidad del Tolima.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTomlinson, IPM
 
dc.contributor.authorDunlop, M
 
dc.contributor.authorCampbell, H
 
dc.contributor.authorZanke, B
 
dc.contributor.authorGallinger, S
 
dc.contributor.authorHudson, T
 
dc.contributor.authorKoessler, T
 
dc.contributor.authorPharoah, PD
 
dc.contributor.authorNiittymäkix, I
 
dc.contributor.authorTuupanenx, S
 
dc.contributor.authorAaltonen, LA
 
dc.contributor.authorHemminki, K
 
dc.contributor.authorLindblom, A
 
dc.contributor.authorFörsti, A
 
dc.contributor.authorSieber, O
 
dc.contributor.authorLipton, L
 
dc.contributor.authorVan Wezel, T
 
dc.contributor.authorMorreau, H
 
dc.contributor.authorWijnen, JT
 
dc.contributor.authorDevilee, P
 
dc.contributor.authorMatsuda, K
 
dc.contributor.authorNakamura, Y
 
dc.contributor.authorCastellvíBel, S
 
dc.contributor.authorRuizPonte, C
 
dc.contributor.authorCastells, A
 
dc.contributor.authorCarracedo, A
 
dc.contributor.authorHo, JWC
 
dc.contributor.authorSham, P
 
dc.contributor.authorHofstra, RMW
 
dc.contributor.authorVodicka, P
 
dc.contributor.authorBrenner, H
 
dc.contributor.authorHampe, J
 
dc.contributor.authorSchafmayer, C
 
dc.contributor.authorTepel, J
 
dc.contributor.authorSchreiber, S
 
dc.contributor.authorVölzke, H
 
dc.contributor.authorLerch, MM
 
dc.contributor.authorSchmidt, CA
 
dc.contributor.authorBuch, S
 
dc.contributor.authorMoreno, V
 
dc.contributor.authorVillanueva, CM
 
dc.contributor.authorPeterlongo, P
 
dc.contributor.authorRadice, P
 
dc.contributor.authorEcheverry, MM
 
dc.contributor.authorVelez, A
 
dc.contributor.authorCarvajalCarmona, L
 
dc.contributor.authorScott, R
 
dc.contributor.authorPenegar, S
 
dc.contributor.authorBroderick, P
 
dc.contributor.authorTenesa, A
 
dc.contributor.authorHoulston, RS
 
dc.date.accessioned2011-03-18T08:26:13Z
 
dc.date.available2011-03-18T08:26:13Z
 
dc.date.issued2010
 
dc.description.abstractIt is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT. © 2010 Cancer Research UK. All rights reserved.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationBritish Journal Of Cancer, 2010, v. 102 n. 2, p. 447-454 [How to Cite?]
DOI: http://dx.doi.org/10.1038/sj.bjc.6605338
 
dc.identifier.citeulike6209351
 
dc.identifier.doihttp://dx.doi.org/10.1038/sj.bjc.6605338
 
dc.identifier.epage454
 
dc.identifier.hkuros168575
 
dc.identifier.isiWOS:000273728500026
Funding AgencyGrant Number
Cancer Research UK
European Union
Instituto de Salud Carlos IIIFIS 05/1006
08/1359
08/1635
European CommissionFP6 Food-CT-2006-036224
Genome Canada
National Cancer Institute of Canada
Ontario Institute for Cancer Research
Academy of Finland20062011
Sigrid Juselius Foundation
Finnish Cancer Societies
German Genome Network
GACR310/07/1430
Swedish Cancer Foundation
Swedish Research Council
Fondo de Investigacion SanitariaFIS 04/1126
05/2031
05/0071
08/0025
08/1276
03-0070
Xunta de GaliciaPGIDIT07PXIB9101209PR
Fundacion de Investigacion Medica Mutua Madrilena
Ministerio de Educacion y CienciaSAF 07-64873
Asociacion Espanola contra el Cancer
Fundacion Olga Torres
Instituto de Salud Carlos III
NHMRC489418
Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government
Funding Information:

The work of UK groups is supported by grants from Cancer Research UK and the European Union. In Spain, work is supported by grants from the Instituto de Salud Carlos III, grants FIS 05/1006, 08/1359, 08/1635 and European Commission FP6 Food-CT-2006-036224 (VM). In Canada, work is supported by grants from Genome Canada (the ARCTIC Project), the National Cancer Institute of Canada (the CaRE Project) and the Ontario Institute for Cancer Research. In Finland, work is supported by grants from Academy of Finland (Finnish Centre of Excellence Program 20062011), the Sigrid Juselius Foundation, the Finnish Cancer Societies and by the European Union. The work of DFKS is supported by the German Genome Network (NGFNplus). In the Czech Republic, work is supported by GACR 310/07/1430. In Sweden, work is supported by grants from the Swedish Cancer Foundation and the Swedish Research Council. In Barcelona and Santiago (Epicolon), work is supported by grants from Fondo de Investigacion Sanitaria (FIS 04/1126, 05/2031, 05/0071, 08/0025, 08/1276), Xunta de Galicia (PGIDIT07PXIB9101209PR), Fundacion de Investigacion Medica Mutua Madrilena (CRP and SCB), Ministerio de Educacion y Ciencia (SAF 07-64873), Asociacion Espanola contra el Cancer, Fundacion Olga Torres (SCB) and Accion Transversal contra el Cancer (Instituto de Salud Carlos III). CIBERER and CIBEREHD are funded by the Instituto de Salud Carlos III. SCB is supported by a contract from the Fondo de Investigacion Sanitaria (CP 03-0070, Ministerio de Sanidad. Provision of genotyping is gratefully provided by Santiago de Compostela node of the Spanish National Genotyping Center (CeGen). In The Netherlands, work of RH is supported by the Dutch Cancer Society and the European Community, and the work of JTW, TvW, HM and PD is supported by the Dutch Cancer Society (UL2005-3247) and Fonds NutsOhra. In Hong Kong, work is supported by grants from the Michael and Betty Kadoorie Cancer Genetics Research Programme II and by the Bobby Moore Fund of Cancer Research UK. Work in Australia is conducted under the auspices of the Hilton Ludwig Cancer Metastasis Initiative and supported by a grant from the NHMRC (Project Grant 489418). In Japan, this work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The ESTHER and VERDI studies are supported by grants from the Baden Wurttemberg Ministry of Research, Science and Arts and the German Cancer Aid (Deutsche Krebshilfe, Grant M24/95/BR I). The Kiel cohort (POPGEN) is funded through the German Ministry of Education and Reserach through the POPGEN Biobank grant and the Colon Cancer Network of the German National Genome Research Network. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant no. 03ZIK012) and by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of Siemens AG. MME, AV and LC-C have received funding from Cancer Research UK and Universidad del Tolima.

 
dc.identifier.issn0007-0920
2012 Impact Factor: 5.082
2012 SCImago Journal Rankings: 2.311
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2816642
 
dc.identifier.pmid19920828
 
dc.identifier.scopuseid_2-s2.0-75549083862
 
dc.identifier.spage447
 
dc.identifier.urihttp://hdl.handle.net/10722/132166
 
dc.identifier.volume102
 
dc.languageeng
 
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBritish Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshColorectal Neoplasms - genetics
 
dc.subject.meshGenetic Predisposition to Disease
 
dc.subject.meshPenetrance
 
dc.subject.meshPolymorphism, Genetic
 
dc.subject.meshPrognosis
 
dc.subjectAssociation
 
dc.subjectColorectal cancer
 
dc.subjectPolymorphism
 
dc.titleCOGENT (COlorectal cancer GENeTics): An international consortium to study the role of polymorphic variation on the risk of colorectal cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tomlinson, IPM</contributor.author>
<contributor.author>Dunlop, M</contributor.author>
<contributor.author>Campbell, H</contributor.author>
<contributor.author>Zanke, B</contributor.author>
<contributor.author>Gallinger, S</contributor.author>
<contributor.author>Hudson, T</contributor.author>
<contributor.author>Koessler, T</contributor.author>
<contributor.author>Pharoah, PD</contributor.author>
<contributor.author>Niittym&#228;kix, I</contributor.author>
<contributor.author>Tuupanenx, S</contributor.author>
<contributor.author>Aaltonen, LA</contributor.author>
<contributor.author>Hemminki, K</contributor.author>
<contributor.author>Lindblom, A</contributor.author>
<contributor.author>F&#246;rsti, A</contributor.author>
<contributor.author>Sieber, O</contributor.author>
<contributor.author>Lipton, L</contributor.author>
<contributor.author>Van Wezel, T</contributor.author>
<contributor.author>Morreau, H</contributor.author>
<contributor.author>Wijnen, JT</contributor.author>
<contributor.author>Devilee, P</contributor.author>
<contributor.author>Matsuda, K</contributor.author>
<contributor.author>Nakamura, Y</contributor.author>
<contributor.author>Castellv&#237;Bel, S</contributor.author>
<contributor.author>RuizPonte, C</contributor.author>
<contributor.author>Castells, A</contributor.author>
<contributor.author>Carracedo, A</contributor.author>
<contributor.author>Ho, JWC</contributor.author>
<contributor.author>Sham, P</contributor.author>
<contributor.author>Hofstra, RMW</contributor.author>
<contributor.author>Vodicka, P</contributor.author>
<contributor.author>Brenner, H</contributor.author>
<contributor.author>Hampe, J</contributor.author>
<contributor.author>Schafmayer, C</contributor.author>
<contributor.author>Tepel, J</contributor.author>
<contributor.author>Schreiber, S</contributor.author>
<contributor.author>V&#246;lzke, H</contributor.author>
<contributor.author>Lerch, MM</contributor.author>
<contributor.author>Schmidt, CA</contributor.author>
<contributor.author>Buch, S</contributor.author>
<contributor.author>Moreno, V</contributor.author>
<contributor.author>Villanueva, CM</contributor.author>
<contributor.author>Peterlongo, P</contributor.author>
<contributor.author>Radice, P</contributor.author>
<contributor.author>Echeverry, MM</contributor.author>
<contributor.author>Velez, A</contributor.author>
<contributor.author>CarvajalCarmona, L</contributor.author>
<contributor.author>Scott, R</contributor.author>
<contributor.author>Penegar, S</contributor.author>
<contributor.author>Broderick, P</contributor.author>
<contributor.author>Tenesa, A</contributor.author>
<contributor.author>Houlston, RS</contributor.author>
<date.accessioned>2011-03-18T08:26:13Z</date.accessioned>
<date.available>2011-03-18T08:26:13Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>British Journal Of Cancer, 2010, v. 102 n. 2, p. 447-454</identifier.citation>
<identifier.issn>0007-0920</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/132166</identifier.uri>
<description.abstract>It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT. &#169; 2010 Cancer Research UK. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Nature Publishing Group. The Journal&apos;s web site is located at http://www.nature.com/bjc</publisher>
<relation.ispartof>British Journal of Cancer</relation.ispartof>
<subject>Association</subject>
<subject>Colorectal cancer</subject>
<subject>Polymorphism</subject>
<subject.mesh>Colorectal Neoplasms - genetics</subject.mesh>
<subject.mesh>Genetic Predisposition to Disease</subject.mesh>
<subject.mesh>Penetrance</subject.mesh>
<subject.mesh>Polymorphism, Genetic</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<title>COGENT (COlorectal cancer GENeTics): An international consortium to study the role of polymorphic variation on the risk of colorectal cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0007-0920&amp;volume=102&amp;issue=2&amp;spage=447&amp;epage=454&amp;date=2010&amp;atitle=COGENT+(COlorectal+cancer+GENeTics):+an+international+consortium+to+study+the+role+of+polymorphic+variation+on+the+risk+of+colorectal+cancer</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1038/sj.bjc.6605338</identifier.doi>
<identifier.pmid>19920828</identifier.pmid>
<identifier.pmcid>PMC2816642</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-75549083862</identifier.scopus>
<identifier.hkuros>168575</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-75549083862&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>102</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>447</identifier.spage>
<identifier.epage>454</identifier.epage>
<identifier.isi>WOS:000273728500026</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>6209351</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/132166/2/6605338a.pdf</bitstream.url>
</item>
Author Affiliations
  1. Hospital Pablo Tobon Uribe
  2. Institute of Cancer Research London
  3. The University of Hong Kong
  4. Universidad de Santiago de Compostela
  5. Universitair Medisch Centrum Groningen
  6. Ontario Institute for Cancer Research
  7. Royal Melbourne Hospital
  8. Universidad del Tolima
  9. University of Helsinki Faculty of Medicine
  10. Institut Municipal d'Investigacio Medica
  11. Karolinska Institutet
  12. Fondazione IFOM Istituto Firc di Oncologia Molecolare
  13. University of Cambridge
  14. Universitätsklinikum Schleswig-Holstein Campus Kiel
  15. Universitat de Barcelona
  16. University of Toronto
  17. University of Oxford
  18. University of Tokyo
  19. Cancer Care Ontario
  20. University of Ottawa, Canada
  21. University of Newcastle, Australia
  22. Leiden University Medical Center - LUMC
  23. University of Edinburgh
  24. Institute of Experimental Medicine, Academy of Sciences of the Czech Republic
  25. German Cancer Research Center
  26. null